Vyriad
PrivateLast Round
Series B
Dec 23, 2025
Total Funding Raised
$97.9M
Company Overview
Vyriad is a biotechnology company specializing in targeted genetic therapies that utilize engineered viruses and viral vectors to deliver genes directly to specific cells, supporting oncolytic virotherapy and gene editing applications in various cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vyriad Comps
Public and private peers based on sector, stage, and business model.
Vyriad Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 23, 2025 | ||||
| Series B | May 17, 2022 | ||||
| Grant | Dec 1, 2020 | ||||
| Corporate Funding | Nov 6, 2019 | ||||
| Convertible Debt | May 10, 2018 | ||||
Series A | Jul 1, 2017 |
Key People
Founding team and executive leadership
Vyriad Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Mirae Asset | Series B |
| Rochester Area Economic Development, Inc. | Convertible Debt, Series B |
| Southeast Minnesota Capital Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 16, 2025
Presented at the ASH 2025 conference.
- Dec 16, 2025
Announced lead in vivo CAR T candidate, VV169, with supporting clinical data.
Vyriad Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vyriad's valuation, stock price, and market status.
